surmount 4 tirzepatide Shifts in body mass index category with and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials tirzepatide surmount 3 once weekly

Reported side effects include swelling, discomfort, and erythema at the injection site

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) have an unparalleled evidence base for reducing hospitalizations for heart failure (particularly in HFrEF) and slowing the progression of chronic kidney disease

KPV's ability to reduce intestinal inflammatory signaling may have downstream implications for metabolic health, particularly in patients where gut inflammation is an upstream driver of broader metabolic dysfunction

Chen X, Ravindra Kumar S, Adams CD, Yang D, Wang T, Wolfe DA, et al

Heart Failure with Preserved Ejection Fraction (HFpEF): Reduces NT-proBNP levels and improves functional capacity